Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sparsomycin
- Development stage
- Discontinued
- Lead developer
- National Cancer Institute
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
Sparsomycin is a cytotoxic antitumor antibiotic originally isolated from the bacterium Streptomyces sparsogenes. It acts as a potent inhibitor of protein synthesis by binding to the large (50S) ribosomal subunit and blocking peptide bond formation through inhibition of peptidyl transferase activity. Sparsomycin inhibits protein synthesis in both prokaryotic (70S) and eukaryotic (80S) ribosomes. While it demonstrated broad-spectrum in vitro activity against various tumor cell lines and was investigated for anticancer use, its clinical development was halted due to significant toxicity—most notably retinopathy observed during early human trials. Today, it is primarily used as a research tool to study mechanisms of translation and ribosome function[1][2][3][4][5][7].
- Other names
- sparsomycinesparsomicinasparsomycinesparsomycinum
02
Targets
PTC (50S ribosomal peptidyl transferase center)
Beyond the preview
Go deeper on sparsomycin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sparsomycin.